| Hepatitis B Virus (HBV) infection was prevalent worldwide, according to the World Health Organization reporting, about 20 million people worldwide have been infected with HBV, of which 350 million people live with chronic HBV infection, about one million people died each year due to liver failure, cirrhosis and hepatocellular carcinoma with HBV infection. China is a high endemic area of HBV infection, about 120 million people are carriers of hepatitis B virus, of which about 30 million people were chronic hepatitis B patients, up to hundreds of thousands of patients died of hepatitis B and its complications each year,HBV infection leads to direct medical costs of 10 billion yuan each year. So HBV infection not only has become a serious medical problem affecting human health, but also has become a heavier economic burden on the social issues, so being active in prevention and treatment of chronic hepatitis B is important, Actively developing ideal anti-HBV drugs is the focus in the field of viral hepatitis research.Objective:To study the anti-hepatitis B virus effect of HH Capsules and its part of the mechanism in vivo and in vitro.Methods:1. HepG2.2.15 were randomized to the control group, the DMSO group (0.1%), the lamivudine groups with different concentration (300,200,100μg/ml) and the HH capsule groups with different concentration (5mg/ml,2.5mg/ml,1.25mg/ml,625μg/ml,312μg/ml,156μg/ml,78μg/ml,39μg/ml,20μg/ml,10μg/ml), All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of the day 2,4,6, CCK-8 was used to detect drug toxicity to find the maximum non-toxic concentration, Enzyme Linked Immunosorbent Assay (ELISA) was usede to detect hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg),Fluorescence Quantitative Polymerase Chain Reaction (FQ-PCR) was used to detect hepatitis B virus DNA (HBVDNA).2. Duck hepatitis B model was preparaed by using Duck hepatitis B virus blood,Duck hepatitis B were randomly divided into the model group,the lamivudine group (100mg/kg-d)and the HH capsule groups with the high(10g/kg-d), medium (5g/kg-d) and low (2.5g/kg-d) doses respectively, after giving the appropriate treatment, at the time of the day 10, day 13, ELISA was usede to detect serum DHBsAg, FQ-PCR was used to detect serum DHBVDNA.3. HepG2.2.15 were randomized to the DMSO group, HH capsule groups with High (312μg/ml) and low (78μg/ml) doses, All groups were given the appropriate culture medium, medium was changed once every 2 days, at the time of day 6, FQ-PCR was usede to detect the intracellular Signal Transducers and Activators of Transcription1 (STAT1), STAT2, IFN-stimulated gene factor 3(ISGF3),2' 5'-Oligoadenylate Synthetase(2'5'-OAS),RAN-dependent protein kinase (PKR) mRNA level, the intracellular protein of OAS, PKR was detected by Western Bloting.Results:In vitro experiment,it shows that, to different degree, HH capsules could reduce the quantity of extracellular HBsAg, HBeAg, HBV DNA and the intracellular HBV DNA in a time and dose-dependent manner.and the HH capsule could increase the intracellular STAT1, STAT2, ISGF3, OAS, PKR mRNA level and enhance the OAS, PKR protein. In vivo experiment,it shows that the HH capsule could reduce the quantity of serum. DHBsAg and DHBV DNA,without virus rebounding after drug withdrawal.Conclusion:HH Capsules has definite anti-HBV effect in vivo and in vitro,likely relating to regulating the JAK-STAT signaling pathway.
|
PDF Full Text Request